PRAC adopted an extension of indication for Gazyvaro for the treatment of adults with primary membranous nephropathy, based on results from the WA41937 (MAJESTY) study. (European Medicines Agency) - Oct 25, 2026 - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes
of meeting on 31 Aug – 3 Sep 2026:
Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, and 6.6 of the SmPC
were updated.
PRAC • Immunology
|